Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Safety and efficacy of arterial injection of tirofiban in treating ischemic stroke beyond the window period

Qiongwen Rong^1,2, Fenglei Chen^1,2, Yuanyuan Ma^1,2 , Yi Cai^1,2

¹Department of Neurology, The First Affiliated Hospital of Hainan Medical University, Haikou 570102, China; ²The First Clinical Medicine College, Hainan Medical University, Haikou 571199, China.

For correspondence:- Yuanyuan Ma Email: mayuanyuan@hainmc.edu.cn Tel:+8689866528133

Accepted: 28 August 2023 Published: 30 September 2023

Citation: Rong Q, Chen F, Ma Y, Cai Y. Safety and efficacy of arterial injection of tirofiban in treating ischemic stroke beyond the window period. Trop J Pharm Res 2023; 22(9):1975-1981 doi: 10.4314/tjpr.v22i9.28

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the efficacy of intraarterial administration of tirofiban for stroke treatment beyond the conventional window period and evaluate its impact on prognosis.

Methods: A retrospective study was conducted on ninety (90) acute ischemic stroke patients admitted to The First Affiliated Hospital of Hainan Medical University, Haikou, China from July 2021 to October 2022. The patients were divided into Tirofiban group (50) and non-Tirofiban group (40) based on whether the patients received arterial clopidogrel. National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS) and Barthel index (BI) scores were used to evaluate adverse drug reactions and its impact on prognosis for patients with symptoms onset within 6 - 24 h.

Results: No significant differences were observed between the groups in terms of age, gender, medical history, personal history, blood indicators and neurologic function scores (p > 0.05). The median NIHSS score on admission and after 24 h of treatment was 4 in both groups and 3 in both groups after 72 h of treatment. However, after 7 days of treatment, the median NIHSS score was lower in Tirofiban group (2.0) than in non-Tirofiban group (2.5; p > 0.05). Tirofiban group demonstrated higher rates of effective treatment and good prognosis compared to non-Tirofiban group. Importantly, there was no significant difference in the occurrence of adverse reactions between the two groups (p > 0.05).

Conclusion: Tirofiban, given via the arteries, improves neurological functions following hyper-acute stroke even beyond the window period and without adverse reactions. It is a safe and effective antiplatelet drug for late-life treatment. For future studies, it will be necessary to broaden the treatment scope and gather more robust and reliable data in order to enhance data quality.

Keywords: Cerebral infarction beyond time window, Tirofiban, Arterial injection